Navigation Links
Mathew to Lead PPD Drug Development Operations and Expansion in India

Company announces second office in Mumbai

WILMINGTON, N.C., Dec. 12 /PRNewswire-FirstCall/ -- PPD, Inc. (Nasdaq: PPDI) today announced the appointment of Philip Mathew, M.D., as director of strategic development, to lead the company's Phase II-IV operations and expansion in India.

Dr. Mathew will provide strategic leadership for PPD's drug development business on the Indian subcontinent, including clinical project management and patient recruitment for key therapeutic areas. He will also be responsible for identifying and helping to develop new clinical sites and business opportunities as well as liaising with local and national government departments.

"A native of India, Dr. Mathew brings extensive clinical trials experience and in-depth knowledge of the healthcare industry in this country," said Simon Britton, vice president of clinical operations for PPD in Asia. "His leadership will enable us to strengthen our presence in this important global clinical research market as we continue to meet the growing needs of our clients. We are pleased to welcome him to PPD."

The company also announced it is opening a second Mumbai office, where Dr. Mathew will be based. The office, located at the Dynasty facility in the Mumbai business district, expands the company's global footprint for providing clinical services.

Prior to joining PPD, Dr. Mathew was associate medical director at Covance Inc. He had previously served as principal investigator with MDS Pharma Services; attending physician with the Robert Wood Johnson University Hospital; instructor of medicine with the University of Medicine and Dentistry of New Jersey; staff physician with the Clinical Research Center of the Robert Wood Johnson Medical School and University of Medicine and Dentistry of New Jersey; and consultant physician with the Church of South India Mission Hospital.

Dr. Mathew attended St. Joseph's College at Calicut University in Kerala, India, and received bachelor's degrees in medicine and surgery from Calicut Medical College. He earned his medical degree in general medicine from Christian Medical College at Vellore in Tamil Nadu, India. Certified by the American Board of Internal Medicine and in its subspecialty of infectious diseases, Dr. Mathew has authored numerous publications and presentations.

PPD is a leading global contract research organization providing discovery, development and post-approval services as well as compound partnering programs. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 30 countries and more than 10,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help its clients and partners maximize returns on their R&D investments and accelerate the delivery of safe and effective therapeutics to patients. For more information, visit our Web site at

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions about the above-named employee's performance and value to PPD contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making those forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. In addition, other important factors which could cause results to differ materially include the following: the ability to attract and retain key personnel; economic conditions and outsourcing trends in the pharmaceutical, biotechnology and medical device industries and government-sponsored research sector; loss of or delay in large contracts; dependence on collaborative relationships; rapid technological advances that make our products and services less competitive; risks associated with acquisitions and investments, such as impairments; competition within the outsourcing industry; continued success in sales growth; and the other risk factors set forth from time to time in the SEC filings for PPD, copies of which are available free of charge upon request from the PPD investor relations department.



Sue Ann Pentecost

+919 456 5690


Steve Smith

+910 558 7585

Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
3. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
4. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
5. Global Experts Explore Entire Spectrum of Aids Vaccine Development
6. Vical Names Andrew de Guttadauro Vice President, Corporate Development
7. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
8. SemBioSys updates Apo AI development program
9. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
10. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
11. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
Post Your Comments:
(Date:11/30/2015)... - BioAmber Inc. (NYSE: BIOA ), a leader in renewable ... Act on Climate Pledge, alongside more than 140 companies from ... Administration to demonstrate an ongoing commitment to climate action and ... Paris climate negotiations. ... . --> BioAmber uses biotechnology to convert ...
(Date:11/30/2015)... , Nov. 30, 2015  Culprits beware, a ... chemistry professor Jan Halámek, is taking crime scene ...   -->   ... --> --> ... have discovered a straightforward concept for identifying whether ...
(Date:11/30/2015)... Nov. 30, 2015 /PRNewswire/ - Zenith Epigenetics Corp. ("Zenith" or ... Norman C.W. Wong to its Board of Directors to ... Zenith with a wealth of experience as co-founder of Resverlogix, ... --> --> Dr. Wong ... board of directors. Zenith,s long standing expertise in epigenetics and ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... new globally touring exhibition Jurassic World: The Exhibition, opening in March 2016 at ... embark on a worldwide tour including several North American tour dates. The Exhibition ...
Breaking Biology Technology:
(Date:10/29/2015)... YORK , Oct. 29, 2015 ... technology, announced a partnership with 2XU, a global ... to deliver a smart hat with advanced bio-sensing ... and other athletes to monitor key biometrics to ... the strategic partnership, the two companies will bring together ...
(Date:10/27/2015)... October 27, 2015 Munich, ... Gaze Mapping technology (ASGM) automatically maps data from mobile ... Glasses , so that they can be quantitatively ... Munich, Germany , October 28-29, 2015. ... data from mobile eye tracking videos created with ...
(Date:10/26/2015)... 26, 2015 ... adds Biometrics Market Shares, Strategies ... well as Emerging Biometrics Technologies: Global ... its collection of IT and Telecommunications ... --> . ...
Breaking Biology News(10 mins):